# Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

> **NCT04401293** · PHASE3 · COMPLETED · sponsor: **Northwell Health** · enrollment: 257 (actual)

## Conditions studied

- Sars-CoV2
- COVID

## Interventions

- **DRUG:** Enoxaparin
- **DRUG:** Prophylactic/Intermediate Dose Enoxaparin

## Key facts

- **NCT ID:** NCT04401293
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-26
- **Primary completion:** 2021-05-14
- **Final completion:** 2021-05-14
- **Target enrollment:** 257 (ACTUAL)
- **Last updated:** 2021-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04401293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04401293, "Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04401293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*